The LentiVector® platform is the only commercially approved lentiviral-based gene delivery system.
The TRiP SystemTM maximises viral vector production output and standardises downstream process
Oxford BioMedica has developed packaging and inducible producer cell lines that enable a simplified and scalable manufacturing process whil
Oxford BioMedica has developed and optimised all the analytics necessary to support product commercialisation.
Oxford BioMedica’s LentiVector® platform is designed to give the highest safety and efficacy.
The LentiVector® platform integrates automated systems enabling scalable and cost-effective manufacture of lentiviral vectors.
Oxford BioMedica established serum-free suspension production processes to enhance vector output.
Oxford BioMedica is introducing Data Analytics and Artificial Intelligence in its systems to improve productivity and product quality